New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
12:46 EDTCAR, HPQ, MRK, LNKD, ZIP, UNH, SKUL, CAT, JNJOn The Fly: Midday Wrap
Stocks on Wall Street were significantly higher at midday after U.S. lawmakers agreed on a deal to avoid some of the tax hikes associated with the fiscal cliff, but many of the issues remaining were simply pushed off by the last-second agreement. The stop-gap measure puts off the drastic spending cuts that were due to take effect, but it did not eliminate them, and it failed to raise the debt limit, meaning another political showdown is coming. The day’s economic data points went largely unnoticed as most investors breathed a sigh of relief and sent the averages soaring right at the opening bell... ECONOMIC EVENTS: In the U.S., Markit's final reading for December's purchasing managers' index came in at 54.0, which was up from 52.8 a month ago and beat expectations for a downward revision to 53.6. The ISM's December manufacturing PMI had a reading of 50.7, versus the expected 50.5, while the prices paid index came in at 55.5, versus the expected 50.8. A separate report showed construction spending fell 0.3% in November, versus an expected increase of 0.6%. In Europe, Markit's zone-wide PMI edged down to 46.1 in December, compared with its 46.3 preliminary reading and down from 46.2 in November... COMPANY NEWS: Every member of the Dow Jones Industrial Average was higher at midday, with only Merck (MRK), Johnson & Johnson (JNJ) and UnitedHealth (UNH) logging gains of less than 1%. Shares of Hewlett-Packard (HPQ) and Caterpillar (CAT) paced the blue chip index, as each rose over 4%... Reflecting a trend similar to the one seen on the Dow, every S&P sector except for Healthcare was significantly higher... MAJOR MOVERS: Among the notable gainers was Zipcar (ZIP), which rose 48% following its agreement to be acquired for $12.25 per share in cash by Avis Budget (CAR), which also had its shares rise nearly 5%. Among the noteworthy losers were Skullcandy (SKUL), down 14% after Jefferies downgraded the stock to Underperform from Buy, and LinkedIn (LNKD) which fell almost 4% after being downgraded to Equal Weight at Barclays... INDICES: Near 12:30 pm ET, the Dow was up 224.78, or 1.72%, to 13,328.92; the Nasdaq was up 67.24, or 2.23%, to 3,086.75; and the S&P 500 was up 24.81, or 1.74%, to 1,451.00.
News For MRK;JNJ;UNH;HPQ;CAT;ZIP;CAR;SKUL;LNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 23, 2015
07:58 EDTHPQBrean Capital maintains Buy on EMC due to activist, merger potential
Subscribe for More Information
07:46 EDTCATCaterpillar announces intention to repurchase $1.5B of common stock in Q3
Subscribe for More Information
07:45 EDTCATCaterpillar cut FY15 revenue guidance due to currency impacts
Subscribe for More Information
07:40 EDTCATCaterpillar Financial reports Q2 revenue $693M, down 6% from 2Q14
Subscribe for More Information
07:34 EDTCATCaterpillar says global economy remains 'relatively stagnant'
Subscribe for More Information
07:33 EDTCATCaterpillar backs FY15 adjusted EPS $5.00, consensus $4.97
Subscribe for More Information
07:32 EDTCATCaterpillar reports Q2 adjusted EPS $1.27, consensus $1.27
Subscribe for More Information
July 22, 2015
15:26 EDTCATNotable companies reporting before tomorrow's open
Subscribe for More Information
14:37 EDTCATCaterpillar technical comments ahead of earnings
The shares are testing the $80 area on the downside ahead of results. On a long-term chart of five years or more, it is clear how important $80 has been as a support. Since 2010 it has only been broken once in any major way. If the news is sufficiently bearish, this support could give way and allow the preceding downtrend to resume. Support levels to watch would be at $78.19 which is the 52-week low, $75.80, and $71.78. If the news is a bullish surprise, the first major test of resistance would come at the 10-month moving average which was last at $87.55. It would take a breakout above the 10-month to turn the short-term trend bullish, with next resistance at $89.62.
14:22 EDTCATCaterpillar July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
13:31 EDTCATEarnings Watch: Wells Fargo says Caterpillar revenue consensus likely too high
Subscribe for More Information
10:37 EDTCATCaterpillar June data suggests consensus revenue view too high, says Wells Fargo
Subscribe for More Information
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
09:34 EDTCATCaterpillar falls, levels to watch
The stock is down 1.7% to $80.83 at time of writing. A big level to watch is the 52-week low at $78.19, which may get retested. Resistance is at $81.78.
09:17 EDTCATCaterpillar reports retail machines sales down 14% in three months end June
Caterpillar reported in a regulatory filing that its total retail machines sales were down 14% on a three month rolling basis in June. For reference, retail sales of machines were down 12% in the period ending in May and were down 11% in the period ending in April. The company reported world Resources Industries sales down 13% in the June period, which was worse than the 8% drop in the May end period. Construction Industries world sales were down 16%, worse than the 14% drop in the May period. Total Energy & Transportation Retail Sales were down 10% in the June end period, which was worse than the 6% decline seen in the May period.
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
July 21, 2015
14:24 EDTHPQEarnings Watch: EMC reports amid M&A speculation in sector
Subscribe for More Information
07:52 EDTHPQHP announces renewable energy agreement with SunEdison
Subscribe for More Information
06:19 EDTHPQSilicon Valley giants side with Samsung in battle with Apple, InsideSources says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use